Want to see IN:POLYMED full AI Analyst Report?
POLYMED Stock Chart & Stats
₹1666.50
₹16.70(1.00%)
At close: 4:00 PM EDT
₹1666.50
₹16.70(1.00%)
Day’s Range― - ―
52-Week Range₹1,184.00 - ₹2,093.95
Previous CloseN/A
Volume148.38K
Average Volume (3M)10.53K
Market Cap
₹160.79B
Enterprise Value₹116.55B
Total Cash (Recent Filing)₹8.27B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)50.9
Beta1.19
Next Earnings
Nov 02, 2026EPS Estimate
8.72Next Dividend Ex-DateN/A
Dividend Yield0.22%
Share Statistics
EPS (TTM)31.09
Shares Outstanding101,361,465
10 Day Avg. Volume14,507
30 Day Avg. Volume10,528
Financial Highlights & Ratios
PEG Ratio-5.93
Price to Book (P/B)4.19
Price to Sales (P/S)6.93
P/FCF Ratio-216.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)39.27
Revenue Forecast (FY)₹23.22B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRevenue increased from approximately ₹7.9B to ₹18.8B across the last five annual periods, with consistently strong growth rates. This scale-up indicates expanding demand and gives Poly Medicure a broader base over which to leverage its medical-device portfolio and manufacturing platform.
Healthy ProfitabilityHealthy gross and net margins, with net margin in the mid-to-high teens to roughly 20%, show that growth has translated into solid profitability. Maintaining this earnings profile would support reinvestment in products, capacity and market expansion, provided recent EBIT pressure does not persist.
Conservative LeverageDebt-to-equity generally stayed around 0.07–0.14 in the years provided, while equity and assets expanded meaningfully. This conservative leverage profile provides financial resilience and preserves borrowing capacity to fund growth or absorb operational volatility.
Bears Say
Weak Cash ConversionFree cash flow was negative in most years shown, including FY2026 and FY2025, while operating cash flow covered only about 0.54–0.76x of net income where provided. Persistent cash conversion weakness can constrain self-funded expansion and reduce flexibility despite reported profits.
Recent EBIT DeclineFY2026 EBIT fell materially from FY2025 even though revenue increased. A divergence between sales growth and operating profit signals potential cost pressure or one-off effects; if sustained, it could weaken margin durability and limit the earnings benefit of further expansion.
Contracting EPSReported EPS growth was -12.86%, indicating earnings per share contracted despite 18.31% revenue growth. This weak conversion of top-line expansion into per-share earnings can limit internal compounding and highlights the need for improved profitability and operating efficiency.
Poly Medicure Limited News
POLYMED FAQ
What was Poly Medicure Limited’s price range in the past 12 months?
Poly Medicure Limited lowest stock price was ₹1184.00 and its highest was ₹2093.95 in the past 12 months.
What is Poly Medicure Limited’s market cap?
Poly Medicure Limited’s market cap is ₹160.79B.
When is Poly Medicure Limited’s upcoming earnings report date?
Poly Medicure Limited’s upcoming earnings report date is Nov 02, 2026 which is in 17 days.
How were Poly Medicure Limited’s earnings last quarter?
Poly Medicure Limited released its earnings results on Aug 07, 2026. The company reported ₹8.49 earnings per share for the quarter, beating the consensus estimate of ₹7.08 by ₹1.41.
Is Poly Medicure Limited overvalued?
According to Wall Street analysts Poly Medicure Limited’s price is currently Overvalued.
Does Poly Medicure Limited pay dividends?
Poly Medicure Limited pays a Annually dividend of ₹3.5 which represents an annual dividend yield of 0.22%. See more information on Poly Medicure Limited dividends here
What is Poly Medicure Limited’s EPS estimate?
Poly Medicure Limited’s EPS estimate is 8.72.
How many shares outstanding does Poly Medicure Limited have?
Poly Medicure Limited has 101,361,465 shares outstanding.
What happened to Poly Medicure Limited’s price movement after its last earnings report?
Poly Medicure Limited reported an EPS of ₹8.49 in its last earnings report, beating expectations of ₹7.08. Following the earnings report the stock price went down -0.971%.
Which hedge fund is a major shareholder of Poly Medicure Limited?
Currently, no hedge funds are holding shares in IN:POLYMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Poly Medicure Limited
Poly Medicure Limited (PML) specializes in the production and distribution of a wide array of medical devices. Its extensive product portfolio encompasses a comprehensive range of infusion equipment, including IV cannulas, midline and arterial catheters, three-way stopcocks, various infusion sets (standard, safety winged, and measured volume), manifolds, extension lines, stylets/mandrins with luer locks, vial access spikes, central venous catheters, CVP manometers, needle-free connectors, pre-filled syringes, vascular access devices, and blood administration sets. The company also supplies diverse feeding solutions, such as nasogastric, infant, and gastro-duodenal feeding tubes, alongside umbilical catheters. Urology offerings include urine collection bags (with or without measured volume meters), Foley balloon catheters, irrigation sets, and general urine drainage catheters. For respiratory and anesthesia care, PML manufactures endotracheal tubes, tracheostomy tubes, mucus extractors, ventilator and Bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. The company also provides oncology-specific products. Oxygen and respiratory therapy devices feature endobronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oropharyngeal airways, and various oxygen masks, including variable concentration, reservoir, fixed concentration, and aerosol therapy types. Its renal care segment comprises dialyzers, blood lines, complete dialysis systems, fistula needles, hemodialysis catheters, and peritoneal dialysis and transfusion sets. Surgical drainage products include closed wound suction units, underwater seal drainage systems, high-pressure vacuum bottles, Yankauer suction sets, and thoracic drainage catheters. For phlebotomy and blood diagnostics, PML supplies blood collection tubes, safety blood collection sets, blood collection needles, erythrocyte sedimentation rate pipettes, and luer adaptors. Blood bag systems are also available. Personal protective equipment (PPE) such as face shields and polymasks, along with viral transport medium kits, form part of its offering. Further miscellaneous medical disposables encompass insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, and universal caps. Established in 1995, the company is headquartered in New Delhi, India.
Technical Analysis
Opto Circuits (India) Limited
―
Viyash Scientific
―
Shaily Engineering Plastics Limited
―
Tarsons Products Limited
―
Fischer Medical Ventures Ltd
―








